Search PubMed⌕ Search

Biomedical subjects

J Schulz

Publications and source records attributed to J Schulz.

At least 91 records · Page 5Linked to original sources
PubMed1989

Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis.

A total of 317 patients received loratadine, 10 mg once daily, terfenadine 60 mg twice daily, or placebo in a 14-day, double-blind, randomized study in seasonal allergic rhinitis. Four nasal and four nonnasal symptoms were evaluated. At the end point evaluation, mean total scores of combined nasal and nonnasal symptoms decreased from baseline (improved) 46%, 44%, and 35%, respectively, for loratadine, terfenadine, and placebo. The difference between loratadine and placebo treatment was significant (p = 0.03). Loratadine was particularly effective compared with placebo in relieving nasal discharge, sneezing, and itching/burning eyes. Therapeutic response to treatment was good or excellent in 66 (64%) of 103 loratadine-treated patients, 58 (56%) of 104 terfenadine-treated patients, and 48 (47%) of 102 placebo-treated patients. Adverse experiences reported during the study were usually mild or moderate and were not significantly different among the three treatment groups. Sedation (somnolence) was reported by 10 loratadine-treated patients, seven terfenadine-treated patients, and eight placebo-treated patients. Loratadine, 10 mg once daily, was comparable to terfenadine, 60 mg twice daily, and significantly superior to placebo in the symptomatic relief of seasonal allergic rhinitis.

Adolescent↗
PubMed1989

Pattern of oral cytokeratins. III. SDS-electrophoretic analysis and immunoblotting of cytokeratins in leukoplakias and squamous cell carcinomas of the oral mucosa.

The frequency of the occurrence of cytokeratins analyzed SDS-electrophoretically in 20 leukoplakic lesions and 14 squamous cell carcinomas of the oral mucosa has shown a picture of "restlessness" with some quantitative, some qualitative deviations from the locally normal pattern of cytokeratins. In most cases the basic pattern typical for the oral mucosa was still recognizable, except for three highly undifferentiated carcinomas. The variations of the cytokeratin pattern existed independently of the clinical form of leukoplakia and of its histological degree of dysplasia. The striking findings in some, but not all cases were: --the presence of cytokeratin no. 18 as a major component which normally appears rarely and faintly, and of cytokeratin no. 19, which is not normally detectable electrophoretically within the whole oral mucosa; --the absence of cytokeratins no. 1-3 despite of the cornification which was reliably proved by histology; --the appearance of the proteins having molecular mass values of 42 kDa and less which very probably may be the products of partial keratinolysis as evidenced by immunoblotting with monoclonal and polyclonal antibodies to cytokeratins. Among these proteins a proteolytically modified cytokeratin no. 19 of only 38 kDa was found.

Antibodies, Monoclonal↗
PubMed1989

[SDS electrophoretic evaluation of salivary protein adsorption to different dental materials].

After different pretreatments of surface the alloys Sipal, Gisadent KCM 83 and Gisadent NCA and the PMME resin Kallocryl A were contaminated with mixed saliva for 1.5 hours. Thereafter, the proteins which could not washed off with water were desorbed from the materials by using a dodecyl sulphate-containing buffer, and analyzed SDS electrophoretically and densitometrically. The pattern of the proteins desorbed reflected a fairly unspecific adsorption of the salivary proteins independent on the kind of the dental material used. Whereas the ranges of the low (10-25 kDa) and the high (greater than 50 kDa) molecular mass polypeptides share nearly equal quotas in the protein pattern of the original saliva, a generally higher portion (68-99%) of the smaller polypeptides was shown among the proteins desorbed from the materials. This effect was especially marked after a shot-peening of alloys and a very high polishing of resin. A somewhat higher percentage of the larger proteins (18-51%) were desorbed from the materials which were pretreated by fine-smoothing or sandblasting.

Adsorption↗
PubMed1989

[Phosphoethanolamine--a substrate of alkaline phosphatase isolated from rat calvaria].

Alkaline phosphatase from calvaria of 8 to 12-day-old Wistar rats was purified to electrophoretic homogeneity by a simple procedure (homogenisation, solubilisation by Triton X-100, DEAE-Sephacel ion exchange chromatography). For the holoenzyme, a Mr of about 160 kDa was determined, and it seems to consist of two identical subunits. The pH optima for the hydrolysis of phosphoethanolamine and p-nitrophenylphosphate are 10.0 and pH 9.0-10.5, respectively. The rate constants for the hydrolysis of phosphoethanolamine, p-nitrophenylphosphate and other phosphomonoesters at pH 10.0 are comparable, but the Km values differ by one to two orders of magnitude. At physiological pH (7.5) the maximum hydrolysis rate of the substrates phosphoethanolamine and p-nitrophenylphosphate was only 8% and 5%, respectively, of that determined at the pH optimum. On the basis of the kinetic data an in vivo function of alkaline phosphatase in bones as a monophosphate ester hydrolyzing enzyme seems unlikely.

Alkaline Phosphatase↗
PubMed1988

Expression of an ouabain-resistant Na,K-ATPase in CV-1 cells after transfection with a cDNA encoding the rat Na,K-ATPase alpha 1 subunit.

We have used a gene transfer system to investigate the relationship between expression of the rat Na,K-ATPase alpha 1 subunit gene and ouabain-resistant Na,K-ATPase activity. A cDNA clone encoding the entire rat Na,K-ATPase alpha 1 subunit was inserted into the expression vector pSV2neo. This construct (pSV2 alpha 1) conferred resistance to 100 microM ouabain to ouabain-sensitive CV-1 cells. Hybridization analysis of transfected clones revealed the presence of both rat-specific and endogenous Na,K-ATPase alpha 1 subunit DNA and mRNA sequences. A single form of highly ouabain-sensitive 86Rb+ uptake was detected in CV-1 cells, whereas two distinct classes of ouabain-inhibitable uptake were observed in transfectants. One class exhibited the high ouabain sensitivity of the endogenous monkey Na,K-ATPase, while the second class showed the reduced ouabain sensitivity characteristic of the rodent renal Na,K-ATPase. Examination of the ouabain-sensitive, sodium-dependent ATPase activity of the transfectants also revealed a low affinity component of Na,K-ATPase activity characteristic of the rodent kidney enzyme. These results suggest that expression of the rat alpha 1 subunit gene is directly responsible for ouabain-resistant Na,K-ATPase activity in transfected CV-1 cells.

Algorithms↗
PubMed1988

Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis.

The efficacy and safety of loratadine, 40 mg once daily, were compared with terfenadine, 60 mg twice daily, and placebo in controlling symptoms of ragweed hay fever. The study was a randomized, multicentric, parallel-group, double-blind design involving 280 patients divided into three groups receiving either loratadine, terfenadine, or placebo for a period of 14 days in the autumn of 1984. Both loratadine and terfenadine demonstrated a statistically greater reduction in symptom score compared to placebo. They were not statistically different from each other, and there was no statistical difference in the incidence of side effects between the two drugs.

Adolescent↗
PubMed1988

Pattern of oral cytokeratins: I. SDS-electrophoretic analysis of the frequency of cytoskeletal keratins in the normal human mucosa of mouth.

In the SDS-electrophoretic pattern of cytokeratins of the normal human mouth mucosa one has to distinguish between the cytokeratins which occur continually and stamp the organ and site specificity of pattern, from those not always detectable. The cytokeratins no. 5, 6/11, and 14/15 are solidly expressed in the whole oral mucosa, no. 1 only in the regions forming a stratum corneum, no. 3 and 16 in the masticatory mucosa, and no. 8 in gingiva and the lining mucosa. Moreover, no. 16 and 18 in the lining mucosa and no. 2, 4, 17, and 18 in the masticatory mucosa appear as minor components with interindividually varying frequency. The highest variability of the cytokeratin pattern exists in the specialized mucosa.

Cytoskeleton↗
PubMed1988

Pattern of oral cytokeratins. II. SDS-electrophoretic analysis of cytokeratins in reactive hyperkeratoses and Lichen ruber planus of the oral mucosa.

In SDS-electrophoresis the hyperortho- and hyperparakeratoses showed cytokeratin patterns fairly similar to those in the normal masticatory mucosa in cases of reactive hyperkeratosis due to mechanical stimulatory action; however, in Lichen ruber planus they agreed only incompletely. The site-specific, normally stably expressed cytokeratins of the mucosa-type concerned were likewise regularly demonstrable in the pathologically changed tissue specimens under study, except cytokeratin no. 1 which is known to be a reliable indicator of keratinocyte cornification merely in orthological but not in pathological conditions. Deviating from the normal cytokeratin pattern in the oral mucosa, a more frequent and more expressed occurrence of cytokeratins no. 17 and 18 was observed in Lichen ruber planus. In 4 extraordinarily reactive hyperkeratoses, among these 2 papillomas the cytokeratins no. 7/13 were present.

Biopsy↗
PubMed1988

Comparative tolerability of two formulations of Rhinalar (flunisolide) nasal spray in patients with seasonal allergic rhinitis.

This double-blind, randomized, crossover study compared the incidence of nasal burning and stinging, as well as overall tolerability of the currently marketed formulation of Rhinalar (original formulation) to a new formulation of Rhinalar containing less propylene glycol. In addition, patient and investigator subjective evaluations were used to compare the effectiveness of the test medications in controlling the nasal symptoms of seasonal allergic rhinitis. A total of 122 patients were enrolled in this 4-week trial. Each patient received one formulation of Rhinalar for 2 weeks and then crossed over to receive the alternate formulation for an additional 2 weeks. Eighteen patients withdrew from the trial prematurely. Ten patients were lost to follow-up and eight withdrew due to side effects and/or inadequate therapeutic response. Statistical comparisons of patient evaluations of nasal burning and stinging with the two formulations of Rhinalar showed a very significant difference in terms of severity (P less than .001), duration (P less than .001), and tolerability (P = .006) in favour of the new formulation. A reduction in severity of throat irritation with the new formulation was also shown to be statistically significant (P = .006). Nausea, headache, and other side effects including watery eyes, taste perversion, and runny nose were seldom reported with either test medication. Both formulations were shown to be equally effective in relieving the nasal symptoms of seasonal allergic rhinitis. The considerable reduction in nasal burning and stinging and throat irritation with the new formulation of Rhinalar was shown to enhance patient acceptability and may lead to better compliance.

Administration, Inhalation↗
PubMed1987

Modification of a critical care ventilator for anesthesia use.

Some critically ill patients require ventilatory support during surgery that exceeds the capabilities of most anesthesia ventilators. We modified an Emerson 3MV ventilator for anesthesia use and measured delivered concentrations of isoflurane during simulated ventilation of a test lung with oxygen flow rates ranging from 5 to 45 L/min. Each measurement was made at atmospheric pressure and incremental levels of 5, 10, 15, and 20 cm H2O PEEP. The delivered anesthetic concentrations were stable at oxygen flow rates of 12.5 to 20 L/min and were unaffected by PEEP changes.

Anesthesia, Inhalation↗
PubMed1987

[Significance of immunohistochemistry in neuro-oncology. V. Keratin as a marker for epithelial differentiation of primary and secondary intracranial and intraspinal tumors].

Intermediate filament keratin is regarded as a good marker for epithelial and mesothelial tumors. In the intracranial and intraspinal spaces keratin has been demonstrated only in the endocrine cells of the adenohypophysis, squamous epithelial islands in the pars tuberalis of the hypophysis and in the choroid plexus epithelium. Since gliomas and meningiomas do not express keratin, this marker provides an additional help for differentiating between primary and secondary CNS tumors. Indirect immunofluorescence using an anti-keratin serum was used in a retrospective search for keratin in 80 tumors of the cranium and intraspinal space. Of the primary CNS tumors keratin positivity occurred in craniopharyngiomas, epidermoid tumors, pituitary adenomas, chordomas, a plexus papilloma as well as in the majority of germ cell tumors. Only 3 renal cell carcinoma metastases of 21 metastatic epithelial cell tumors (7 bronchial carcinomas, 6 breast cancers, 6 renal carcinomas, 1 rectum carcinoma, 1 cervix carcinoma) were keratin-negative. Similar findings were made in two melanoma metastases which we examined, whereas in a seminoma metastasis a few keratin expressing cells were found. Primary CNS tumors such as myxopapillary ependymomas, medulloepitheliomas, malignant meningiomas and paragangliomas which are often difficult to distinguish from these metastases proved to be keratin negative.

Brain Neoplasms↗